Di Bona D, Magistà S, Masciopinto L, et al. - Researchers performed this retrospective review and analyzed patients with allergic rhino-conjunctivitis with or without asthma, who were treated with subcutaneous immunotherapy (SCIT) to mites and pollens from 1988 to 2018, to determine the rate of side effects (SE) to SCIT as well as treatment compliance at a hospital medically supervised facility. A total of 3,037 SCIT courses were received by 2,200 patients (50.2% males; mean age 29.4 ± 11.7 years). The delivered injections were 91,187 in total, with a mean SCIT duration of 2.5 ± 1.9 years. There were 957 compliant patients (43.5%) as they finished the minimally needed treatment duration of 3 years. During the study period, 42 anaphylactic reactions (in 29 patients) were reported; two of these were severe. Independent link with SE was displayed by female gender, number of vaccines administered (2 vaccine vs 1 vaccine) and year of SCIT inception (1996–2018 vs 1988–1995). Findings revealed the safety as well as the good tolerability of SCIT, although SCIT was not absolutely free of risk. Scope of further improvement of treatment compliance was also acknowledged.